BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tß4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tß4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation. Research on the identification and characterization of the key factors needed to trigger stem cell differentiation and maturation are among the most active areas of medical research and are believed to be fundamental to the future development of breakthrough therapeutic agents. Additional research projects are focused on understanding the mechanisms of action and role of Tß4 in diverse areas of biomedicine ranging from cardiovascular disease and kidney fibrosis to neurological disorders and memory. The research funded by these grants will advance our understanding of the basic mechanisms of Tß4’s actions and its clinical potential.
